ArticleImmunity2026
Multiomic analysis of ART-interruption cohorts identifies cell-extrinsic and -intrinsic mechanisms driving lymphocyte-mediated control of HIV rebound.
Abstract read
In one paragraph
Article in Immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Tongcui MaGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Ashley F GeorgeGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Zichong LiGladstone Institutes, San Francisco, CA 94158, USA.
Reuben ThomasGladstone Institutes, San Francisco, CA 94158, USA.
Kailin YinGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Min-Gyoung ShinGladstone Institutes, San Francisco, CA 94158, USA.
Mauricio MontanoGladstone Institutes, San Francisco, CA 94158, USA.
Yusuke MatsuiGladstone Institutes, San Francisco, CA 94158, USA.
Manickam AshokkumarDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Kyrlia YoungGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Julia PrigannGladstone Institutes, San Francisco, CA 94158, USA.
Julie FrouardGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Sabrina LeddyDepartment of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.
Maisha AdibaLeibniz Institute of Virology, Hamburg, Germany.
Christina HerrdeLeibniz Institute of Virology, Hamburg, Germany.
Ulrike C LangeLeibniz Institute of Virology, Hamburg, Germany; Institute of Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Cedric FeschotteDepartment of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.
Douglas F NixonInstitute of Translational Research, Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA.
Edward P BrowneDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Nancie M ArchinDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Jonathan Z LiDepartment of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Davey SmithSchool of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Steven DeeksUniversity of California, San Francisco, San Francisco, CA 94158, USA.
Ole S SøgaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Martin TolstrupDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Sulggi LeeUniversity of California, San Francisco, San Francisco, CA 94158, USA.
Satish K PillaiUniversity of California, San Francisco, San Francisco, CA 94158, USA; Vitalant Research Institute, San Francisco, CA 94105, USA.
Mohamed Abdel-MohsenDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Center for Human Immunobiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Potocsnak Longevity Institute, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Katherine S PollardGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA; Biohub, San Francisco, CA 94158, USA.
Robert SilicianoDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Melanie OttGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA; Biohub, San Francisco, CA 94158, USA. Electronic address: melanie.ott@gladstone.ucsf.edu.
Warner C GreeneGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: warner.greene@gladstone.ucsf.edu.
Nadia R RoanGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: nadia.roan@gladstone.ucsf.edu.
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MUCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4MHOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6MSan Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5MNorthwestern University Clinical Trial UnitUM1AI069471 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Chad J Achenbach · 2012 to 2026
$24.6MHigh-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Ya-Chi Ho, Jonathan Li · 2022 to 2026
$10.1MThe heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3MProject 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruptionP01AI131374 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI PILLAI, SATISH KUMAR · 2017 to 2021
$8.5MRole of Factor Acetylation in the Regulation of HIV TranscriptionR37AI083139 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Melanie Maria Ott · 2019 to 2026
$5.5MNIAID NIH HHS P01 AI131374NIAID NIH HHS P01 AI169606NIAID NIH HHS P01 AI169768NIAID NIH HHS R01 AI147777NIAID NIH HHS R01 AI165079NIAID NIH HHS R01 AI183286NIAID NIH HHS R01 AI189353NIAID NIH HHS R21 AI172060NIAID NIH HHS R37 AI083139NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069471NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI164559NIAID NIH HHS UM1 AI164567NIA NIH HHS R01 AG092241NIDDK NIH HHS R01 DK123733NIDDK NIH HHS R01 DK131526
Abstract
Immunological mechanisms regulating HIV rebound after antiretroviral therapy (ART) interruption remain unclear. We examined relationships between host factors, HIV reservoir, and HIV time-to-rebound after analytical treatment interruption (ATI) by characterizing pre-ATI peripheral blood mononuclear cells (PBMCs) from 75 ART-suppressed people with HIV (PWH) using high-parameter methods. Across interventional (CLEAR, TEACH, and REDUC) and non-interventional (A5345) cohorts, delayed rebound was not associated with intact HIV. Cohort-specific immune effectors were associated with delayed rebound. RNA sequencing of CD4
Indexed as
CD4-Positive T-LymphocytesHIV-1HIV InfectionsAnimalsAnti-HIV AgentsCohort StudiesDNA-Binding ProteinsFemaleHumansMaleMetforminTranscription FactorsTreatment InterruptionViral LoadAnti-HIV AgentsDDIT4 protein, humanDNA-Binding ProteinsMetforminTranscription FactorsCD4(+) T cellsHIV persistencemetforminNK cellsT cellszinc finger transcription factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.